Drugs.com - Clinical Trials

Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

SPRING HOUSE, Pa. (March 8, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO)...

Mar 9, 2025 - 22:05
 0
Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis
SPRING HOUSE, Pa. (March 8, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO)...
Read More

Tags:

Previous Article

How to Become a Firefighter: A Step-by-Step Guide

Next Article

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite ...

Related Posts

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025  0

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025  0

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Novo Nordisk Successfully Completes Phase 1b/2a Trial w...

Feb 9, 2025  0